The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to ...
Findings from an exploratory 2a study showed improvements in patients with cancer cachexia with PH284 compared with placebo.
The FDA approved acalabrutinib in combination with bendamustine and rituximab for adults with previously untreated mantle ...
The FDA has approved sotorasib with panitumumab for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC) ...
Improved education on drug toxicity management, especially within the first 90 days of treatment and regarding individualized ...
Oncology nurses can educate patients on the benefits of subcutaneous administration, including reduced time in the infusion ...
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
Sasanlimab (PF-06801591) added to BCG therapy significantly improved outcomes for patients with BCG-naive, high-risk ...
Panelists discuss practical insights and learning opportunities through interactive examination of a patient case.
An APP’s research is focused on chemo-induced peripheral neuropathy in Black breast cancer survivors and its impact on their long-term quality of life. Given the significant number of breast cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback